Urothelial carcinoma (bladder + upper tract) · line 2 · Pembrolizumab monotherapy

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-PEMBROLIZUMAB-MONO`

ID	`IND-UROTHELIAL-2L-PEMBROLIZUMAB`
Type	Indication
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	`DIS-UROTHELIAL`
Sources	`SRC-KEYNOTE-045-BELLMUNT-2017`

Notes

KEYNOTE-045 5-year follow-up (Bellmunt 2022): ~19% pembrolizumab responders maintained response at 5 years vs 0% with chemotherapy. Pembrolizumab provides durable disease control for ~7% of patients. PD-L1 CPS testing before 2L is informative (CPS ≥10 has stronger predictive value) but is NOT a requirement — benefit seen regardless. REG-PEMBROLIZUMAB-MONO reference required — use standard pembrolizumab 200 mg q3w.

Used By

Algorithms

ALGO-UROTHELIAL-METASTATIC-2L - ALGO-UROTHELIAL-METASTATIC-2L